First medicine targeting BRCA mutations to show clinical benefit in adjuvant setting

Attachments

  • Original document
  • Permalink

Disclaimer

AstraZeneca plc published this content on 03 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 June 2021 21:04:03 UTC.